查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1880596

氨基糖苷類抗生素市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032 年）

Aminoglycosides Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

氨基糖苷類抗生素市場成長驅動因子

受細菌感染病例增加、抗生素技術進步以及對治療複雜呼吸道和泌尿道感染的有效療法的需求不斷增長的推動，全球氨基糖苷類抗生素市場持續穩步增長。根據最新的產業報告，預計到 2024 年，市場規模將達到 18.7 億美元，2025 年將達到 19.2 億美元，到 2032 年將達到 23.5 億美元，複合年增長率 (CAGR) 為 2.95%。 2024 年，北美市場佔主導地位，市場佔有率為 41.17%，這得益於其完善的醫療保健體系、強有力的抗生素管理計劃以及在重症病例管理中對氨基糖苷類抗生素的高採用率。

氨基糖苷類抗生素，如慶大霉素、妥布黴素、阿米卡星、鏈黴素和新黴素，是治療嚴重感染的重要殺菌抗生素。它們獨特的抗菌機制，即與細菌30S核醣體亞基結合並抑制蛋白質合成，使其對革蘭氏陰性菌特別有效。與β-內醯胺類抗生素合併使用，進一步提升了其在加護病房（ICU）中的價值。吸入製劑和半合成衍生物等技術創新，提高了其安全性、給藥途徑和療效。諸如史丹佛大學2022年旨在開發降低聽力損失風險的氨基糖苷類藥物的研究等研發工作，持續提升其市場潛力。

市場動態

市場推動因素

推動市場擴張的關鍵因素是全球泌尿道感染 (UTI) 病例的增加。人口老化、糖尿病患者增加、生活方式改變以及醫院感染等因素正在加速對抗生素的需求。為了因應這些趨勢，各公司正在擴展產品線並推出新的解決方案。 2024 年，Cipla 公司獲得了印度中央藥品監管和監督組織 (CDSCO) 的批准，可在印度銷售其新一代氨基糖苷類抗生素普拉佐米星，用於治療複雜性尿路感染，這反映出該公司加大了商業投資。

市場限制因子

日益嚴重的全球抗菌素抗藥性 (AMR) 威脅對市場成長構成重大障礙。大腸桿菌、肺炎克雷伯菌和綠膿桿菌等病原體的抗藥性正在迅速增強。 2023年，美國疾病管制與預防中心（CDC）報告稱，美國醫院中氨基糖苷類抗藥性革蘭氏陰性菌感染病例呈上升趨勢；2024年，歐洲疾病預防控制中心（ECDC）指出，歐洲部分地區肺炎克雷伯菌血流感染的抗藥性率超過25%。這些趨勢對氨基糖苷類抗生素的長期療效和應用構成了挑戰。

市場機會

儘管存在抗藥性問題，勝肽連接的氨基糖苷類綴合物為恢復現有藥物對多重抗藥性細菌的療效提供了一個有前景的機會。 2025年發表在 "微生物學前沿" （Frontiers in Microbiology）上的一項研究證實了肽-新黴素綴合物與多粘菌素B之間存在顯著的協同作用，表明修飾的氨基糖苷類藥物具有克服酶促藥物失活的潛力。

市場挑戰

主要挑戰在於耳毒性和腎毒性的風險，尤其是在攜帶罕見粒線體突變的個體中。即使在治療範圍內使用，氨基糖苷類抗生素也可能導致不可逆的聽力損失。英國政府在2021年發布的關於治療窗較窄的警告反映了持續存在的安全隱患，這可能會限制其更廣泛的臨床應用。

區隔市場亮點

依代劃分

第三代氨基糖苷類抗生素在2024年引領市場，這得益於感染率的上升和其高療效。策略性授權協議，例如Sifan Pharmaceutical於2022年達成的貝那培南和普拉佐米星的共同開發協議，鞏固了該區隔市場的領先地位。

依應用領域

2024年，由於多重抗藥性銅綠假單胞菌病例的增加以及囊性纖維化盛行率的上升，呼吸道感染成為市場主導領域。美國疾病管制與預防中心 (CDC) 報告稱，美國有35,000人患有囊性纖維化，這推動了對先進吸入型氨基糖苷類藥物的需求。

依給藥途徑

由於其局部活性和較低的全身風險，外用製劑在2024年佔市場主導地位。 2024年，Appili Therapeutics公司推進了其用於治療皮膚利甚曼病的局部用巴龍黴素製劑ATI-1801的研發。

依通路劃分

2024年，零售藥局在全球市場佔主導地位，這主要得益於其便利性的提升和患者的高度信任。 Pharmaprix 2024年的診所擴張計畫也反映了零售通路抗生素銷售的成長。

區域展望

北美仍是最大的區域市場，2024年銷售額達7.7億美元，主要得益於其完善的醫療保健系統和強大的抗生素研發能力。預計到2025年，歐洲市場將達到4.9億美元，主要得益於抗菌藥物管理和監管的加強。亞太地區預計到2025年將達到3.2億美元，主要得益於傳染病負擔的加重和醫藥基礎設施的持續改善。預計2025年，拉丁美洲市場將達到2億美元，新興市場預計將保持溫和成長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要疾病概述（依主要國家/地區劃分，2024 年）
  • 主要國家的監管狀況（2024 年）
  • 主要公司研發管線分析
  • 抗生素治療指引摘要
  • 世衛組織抗生素抗藥性 "優先病原體" 概要
  • 主要產業趨勢：併購，收購、合作等

第五章：全球氨基糖苷類抗生素市場分析、洞察與預測（2019-2032 年）

  • 市場分析、洞察與預測 - 依世代劃分
    • 第一代
    • 第二代
    • 第三代
    • 其他
  • 市場分析、洞察與預測 - 依應用劃分
    • 泌尿道感染
    • 呼吸道感染
    • 皮膚感染
    • 眼部感染
    • 其他
  • 市場分析、洞察與預測 - 依給藥途徑劃分
    • 口服
    • 腸外給藥
    • 其他
  • 市場分析、洞察與預測 - 依銷售額分割管道
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美氨基糖苷類抗生素市場分析、洞察與預測，2019-2032

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲氨基糖苷類抗生素市場分析、洞察與預測，2019-2032

  • 依國家劃分
    • 德國
    • 美國王國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區氨基糖苷類抗生素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲氨基糖苷類抗生素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

章節10：中東和非洲氨基糖苷類抗生素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
  • Amneal Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals PLC
  • Insmed Incorporated
  • Pfizer Inc.
  • Cipla
  • Nordic Group B.V.
  • Lupin
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
Product Code: FBI113880

Growth Factors of aminoglycosides Market

The global aminoglycosides market continues to grow steadily, driven by rising bacterial infections, advancements in antibiotic technologies, and increasing demand for effective treatments for complicated respiratory and urinary tract infections. According to the latest industry report, the market size was USD 1.87 billion in 2024, projected to rise to USD 1.92 billion in 2025, and expected to reach USD 2.35 billion by 2032, expanding at a CAGR of 2.95%. In 2024, North America led the market with a 41.17% share, supported by robust healthcare systems, strong antibiotic stewardship programs, and higher adoption of aminoglycosides for critical care management.

Aminoglycosides-such as gentamicin, tobramycin, amikacin, streptomycin, and neomycin-remain essential bactericidal antibiotics used in treating severe infections. Their unique mechanism of binding to the bacterial 30S ribosomal subunit disrupts protein synthesis, making them especially effective against gram-negative pathogens. Their synergy with B-lactam antibiotics further strengthens their use in intensive care units. Technological innovations, including inhaled formulations and semi-synthetic derivatives, are enhancing safety, delivery, and therapeutic efficiency. Research activities, such as Stanford University's 2022 study aiming to develop hearing-loss-safe aminoglycosides, continue to elevate market potential.

Market Dynamics

Market Drivers

A key driver contributing to market uptake is the rising global prevalence of urinary tract infections (UTIs). Factors such as population aging, increasing diabetes incidence, lifestyle changes, and hospital-acquired infections have accelerated antibiotic demand. Responding to these trends, companies are expanding portfolios and introducing new solutions. In 2024, Cipla received approval from CDSCO to market Plazomicin, a next-generation aminoglycoside for complicated UTIs in India, reflecting growing commercial investments.

Market Restraints

The increasing global threat of antimicrobial resistance (AMR) poses a substantial barrier to market growth. Resistance in pathogens such as E. coli, K. pneumoniae, and P. aeruginosa is rising sharply. CDC reported in 2023 that aminoglycoside-resistant gram-negative infections are spreading across U.S. hospitals, while ECDC noted in 2024 that resistance in K. pneumoniae bloodstream infections exceeded 25% in parts of Europe. These trends challenge the long-term efficacy and adoption of aminoglycosides.

Market Opportunities

Despite resistance concerns, a promising opportunity lies in peptide-linked aminoglycoside conjugates, which restore the effectiveness of existing drugs against MDR organisms. A 2025 Frontiers in Microbiology study revealed strong synergistic action between peptide-neomycin conjugates and polymyxin B, highlighting the potential of modified aminoglycosides to overcome enzymatic drug inactivation.

Market Challenges

A major challenge is the risk of ototoxicity and nephrotoxicity, especially for individuals with rare mitochondrial mutations. Even when dosed within therapeutic ranges, aminoglycosides can cause irreversible hearing loss. The U.K. government's 2021 warning about narrow therapeutic windows reflects ongoing safety concerns that may limit broader clinical adoption.

Segmentation Highlights

By Generation

The third-generation aminoglycosides segment dominated in 2024, supported by increasing infection rates and high efficacy. Strategic licensing agreements-such as Sihuan Pharmaceutical's 2022 collaboration for Benapenem and Plazomicin-reinforce segment leadership.

By Application

In 2024, respiratory tract infections led the market due to rising MDR-Pseudomonas cases and growing cystic fibrosis prevalence. The CDC reported 35,000 people living with CF in the U.S., driving demand for advanced inhaled aminoglycosides.

By Route of Administration

The topical segment dominated in 2024 owing to localized action and lower systemic risk. In 2024, Appili Therapeutics advanced ATI-1801, a topical paromomycin formulation for cutaneous leishmaniasis.

By Distribution Channel

Retail pharmacies led the global market in 2024, driven by improved accessibility and high trust levels among patients. Pharmaprix's 2024 clinic expansion reflects growth in retail-based antibiotic dispensing.

Regional Outlook

North America remained the largest regional market in 2024 with revenues of USD 0.77 billion, backed by established healthcare systems and strong antibiotic R&D. Europe is forecast to reach USD 0.49 billion in 2025, supported by antimicrobial stewardship and regulatory oversight. Asia Pacific is projected to attain USD 0.32 billion in 2025, driven by rising infectious disease burdens and expanding pharmaceutical infrastructure. Latin America is expected to reach USD 0.20 billion in 2025, with moderate growth across emerging markets.

Conclusion

With the market projected to grow from USD 1.87 billion in 2024 to USD 2.35 billion by 2032, the aminoglycosides sector continues to evolve through product innovation, combination therapy expansion, and advanced antibiotic development. Despite AMR and toxicity challenges, sustained R&D and improved drug formulations are expected to support stable long-term market growth.

Segmentation By Generation

  • First Generation
  • Second Generation
  • Third Generation
  • Others

By Application

  • Urinary Tract Infections
  • Respiratory Tract Infection
  • Skin Infections
  • Ophthalmic Infections
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America (By Generation, Application, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Key Diseases, By Key Countries/ Region, 2024
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2024
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Overview of Antimicrobial Treatment Guidelines
  • 4.5. Overview of the Antibiotic resistant "Priority Pathogens" Published by WHO
  • 4.6. Key Industry Developments- Mergers, Acquisitions, Partnerships, etc.

5. Global Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Generation
    • 5.1.1. First Generation
    • 5.1.2. Second Generation
    • 5.1.3. Third Generation
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Urinary Tract Infections
    • 5.2.2. Respiratory Tract Infection
    • 5.2.3. Skin Infections
    • 5.2.4. Opthalmic Infections
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Topical
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Online Pharmacy
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Generation
    • 6.1.1. First Generation
    • 6.1.2. Second Generation
    • 6.1.3. Third Generation
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Urinary Tract Infections
    • 6.2.2. Respiratory Tract Infection
    • 6.2.3. Skin Infections
    • 6.2.4. Opthalmic Infections
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Topical
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Online Pharmacy
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Generation
    • 7.1.1. First Generation
    • 7.1.2. Second Generation
    • 7.1.3. Third Generation
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Urinary Tract Infections
    • 7.2.2. Respiratory Tract Infection
    • 7.2.3. Skin Infections
    • 7.2.4. Opthalmic Infections
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Online Pharmacy
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Generation
    • 8.1.1. First Generation
    • 8.1.2. Second Generation
    • 8.1.3. Third Generation
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Urinary Tract Infections
    • 8.2.2. Respiratory Tract Infection
    • 8.2.3. Skin Infections
    • 8.2.4. Opthalmic Infections
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Topical
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Generation
    • 9.1.1. First Generation
    • 9.1.2. Second Generation
    • 9.1.3. Third Generation
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Urinary Tract Infections
    • 9.2.2. Respiratory Tract Infection
    • 9.2.3. Skin Infections
    • 9.2.4. Opthalmic Infections
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Topical
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Online Pharmacy
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Generation
    • 10.1.1. First Generation
    • 10.1.2. Second Generation
    • 10.1.3. Third Generation
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Urinary Tract Infections
    • 10.2.2. Respiratory Tract Infection
    • 10.2.3. Skin Infections
    • 10.2.4. Opthalmic Infections
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Topical
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
    • 11.2.1. Amneal Pharmaceuticals, Inc.
    • 11.2.2. Hikma Pharmaceuticals PLC
    • 11.2.3. Insmed Incorporated
    • 11.2.4. Pfizer Inc.
    • 11.2.5. Cipla
    • 11.2.6. Nordic Group B.V.
    • 11.2.7. Lupin
    • 11.2.8. Sun Pharmaceutical Industries Ltd.
    • 11.2.9. Dr. Reddy's Laboratories Ltd.

List of Tables

  • Table 1: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 2: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 3: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 4: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 5: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 7: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 8: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 9: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 10: North America Aminoglycosides Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 12: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 13: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 14: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 15: Europe Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 17: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 18: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 19: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 22: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 23: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 24: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 25: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 26: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 27: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 28: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 29: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Aminoglycosides Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Aminoglycosides Market Value Share (%), by Generation, 2024 & 2032
  • Figure 3: Global Aminoglycosides Market Value Share (%), by Application, 2024 & 2032
  • Figure 4: Global Aminoglycosides Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 5: Global Aminoglycosides Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 6: Global Aminoglycosides Market Value Share (%), by Region, 2024 & 2032
  • Figure 7: North America Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 8: North America Aminoglycosides Market Value Share (%), by Generation, 2024
  • Figure 9: North America Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
  • Figure 10: North America Aminoglycosides Market Value Share (%), by Application, 2024
  • Figure 11: North America Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 12: North America Aminoglycosides Market Value Share (%), by Route of Administration, 2024
  • Figure 13: North America Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 14: North America Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
  • Figure 15: North America Aminoglycosides Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Aminoglycosides Market Value Share (%), By Country, 2024
  • Figure 17: Europe Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 18: Europe Aminoglycosides Market Value Share (%), by Generation, 2024
  • Figure 19: Europe Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
  • Figure 20: Europe Aminoglycosides Market Value Share (%), by Application, 2024
  • Figure 21: Europe Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 22: Europe Aminoglycosides Market Value Share (%), by Route of Administration, 2024
  • Figure 23: Europe Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 24: Europe Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
  • Figure 25: Europe Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 28: Asia Pacific Aminoglycosides Market Value Share (%), by Generation, 2024
  • Figure 29: Asia Pacific Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
  • Figure 30: Asia Pacific Aminoglycosides Market Value Share (%), by Application, 2024
  • Figure 31: Asia Pacific Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 32: Asia Pacific Aminoglycosides Market Value Share (%), by Route of Administration, 2024
  • Figure 33: Asia Pacific Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
  • Figure 35: Asia Pacific Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 38: Latin America Aminoglycosides Market Value Share (%), by Generation, 2024
  • Figure 39: Latin America Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
  • Figure 40: Latin America Aminoglycosides Market Value Share (%), by Application, 2024
  • Figure 41: Latin America Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 42: Latin America Aminoglycosides Market Value Share (%), by Route of Administration, 2024
  • Figure 43: Latin America Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
  • Figure 45: Latin America Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 48: Middle East & Africa Aminoglycosides Market Value Share (%), by Generation, 2024
  • Figure 49: Middle East & Africa Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
  • Figure 50: Middle East & Africa Aminoglycosides Market Value Share (%), by Application, 2024
  • Figure 51: Middle East & Africa Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 52: Middle East & Africa Aminoglycosides Market Value Share (%), by Route of Administration, 2024
  • Figure 53: Middle East & Africa Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
  • Figure 55: Middle East & Africa Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 57: Global Aminoglycosides Market Share (%), By Company, 2024